Assessing patients' information needs regarding drug-drug interactions.

OBJECTIVE To assess patients' information needs regarding drug-drug interactions (DDIs) to inform patient DDI education resources. DESIGN Cross-sectional study. SETTING Online (United States in May 2011). PARTICIPANTS Registered users of an online medication monitoring service (MediGuard). INTERVENTION Online questionnaire. MAIN OUTCOME MEASURE Participants' information needs regarding DDIs and perceived importance of questions related to detecting and preventing harm from DDIs. RESULTS Characteristics of the 100 surveyed participants were as follows: 57% women, 88% white, 96% non-Hispanic, 71% retired, mean (±SD) age 65.2 ± 9.7 years (range 35-86). The number of prescription medications ranged from 2 to 22 (median 7) and the number of over-the-counter (OTC) medications from 1 to 10 (4). The most common concerns cited by participants were identification of interacting medications, seriousness of DDIs, interactions with OTC medications, interactions with foods, exacerbating comorbidities, short- and long-term adverse effects, signs and frequency of DDIs, and how to minimize adverse effects. Statistically significant differences based on gender, number of prescriptions, and number of OTC medications were observed in rankings of the importance of some DDI questions ( P < 0.05). CONCLUSION Patient-centered DDI education programs should consider addressing the seriousness of DDIs, the effect of DDIs on comorbidities, and interactions with OTC medications and foods and determining methods for identifying, minimizing, and managing DDIs.

[1]  Edward P. Armstrong,et al.  Identification of serious drug-drug interactions: results of the partnership to prevent drug-drug interactions. , 2004, Journal of the American Pharmacists Association : JAPhA.

[2]  A. Alkhawajah,et al.  The role of pharmacists in patients' education on medication. , 1992, Public health.

[3]  R. Kravitz,et al.  How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[4]  W P McKinney,et al.  Pharmacist recognition of potential drug interactions. , 1999, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[5]  J. Hanley,et al.  The medical office of the 21st century (MOXXI): effectiveness of computerized decision-making support in reducing inappropriate prescribing in primary care. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[6]  P. Bryant,et al.  Potential drug interactions in a physical medicine and rehabilitation clinic. , 1990, American journal of physical medicine & rehabilitation.

[7]  K. Hersberger,et al.  Prevalence and patient awareness of selected potential drug interactions with self‐medication , 2007, Journal of clinical pharmacy and therapeutics.

[8]  M. Bharmal,et al.  Patient preferences for adherence enhancing tools , 2010 .

[9]  Daniel C Malone,et al.  Prescribers’ Knowledge of and Sources of Information for Potential Drug-Drug Interactions , 2008, Drug safety.

[10]  V. Braun,et al.  Using thematic analysis in psychology , 2006 .

[11]  P. Glassman,et al.  Improving Recognition of Drug Interactions: Benefits and Barriers to Using Automated Drug Alerts , 2002, Medical care.

[12]  H. Bernard,et al.  Techniques to Identify Themes , 2003 .

[13]  R. Kravitz,et al.  A decade of controversy: balancing policy with evidence in the regulation of prescription drug advertising. , 2010, American journal of public health.

[14]  E. Brass.  Consumer behavior in the setting of over-the-counter statin availability: lessons from the consumer use study of OTC Mevacor. , 2004, The American journal of cardiology.

[15]  E. Bernasconi,et al.  Assessment of potential drug-drug interactions at hospital discharge. , 2010, Swiss medical weekly.

[16]  R. Hamilton,et al.  Frequency of Hospitalization after Exposure to Known Drug‐Drug Interactions in a Medicaid Population , 1998, Pharmacotherapy.

[17]  V. F. Trewin,et al.  Patient sources of drug information and attitudes to their provision: a corticosteroid model , 2003, Pharmacy World and Science.

[18]  Ida Sim,et al.  A taxonomic description of computer-based clinical decision support systems , 2006, J. Biomed. Informatics.

[19]  E B TRUITT,et al.  Determination of salicylic acid and two metabolites in plasma and urine using fluorimetry for directly measuring salicyluric acid. , 1955, Journal of the American Pharmaceutical Association. American Pharmaceutical Association.

[20]  Michael R. Cohen.  Medication errors : causes, prevention, and risk management , 2000 .

[21]  P. Shekelle,et al.  Systematic Review: Impact of Health Information Technology on Quality, Efficiency, and Costs of Medical Care , 2006, Annals of Internal Medicine.

[22]  C. Moura,et al.  Drug-drug interactions associated with length of stay and cost of hospitalization. , 2009, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[23]  Amy J Grizzle,et al.  Critical issues associated with drug-drug interactions: highlights of a multistakeholder conference. , 2011, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.